Read more
Personalized medicine employing patient-based tailor-made therapeutic drugs is taking over treatment paradigms in a variety of ?elds in oncology and the central nervous system. The success of such therapies is mainly dependent on ef?cacious therapeutic drugs and a selective imaging probe for identi?cation of potential responders as well as therapy monitoring for an early bene?t assessment. Molecular imaging (MI) is based on the selective and speci?c interaction of a molecular probe with a biological target which is visualized through nuclear, magnetic resonance, near infrared or other methods. Therefore it is the method of choice for patient selection and therapy monitoring as well as for speci?c e- point monitoring in modern drug development. PET (positron emitting tomography), a nuclear medical imaging modality, is ideally suited to produce three-dimensional images of various targets or processes. The rapidly increasing demand for highly selective probes for MI strongly pushes the development of new PET tracers and PET chemistry. 'PET chemistry' can be de?ned as the study of positron-emitting compounds regarding their synthesis, structure, composition, reactivity, nuclear properties and processes and their properties in natural and - natural environments. In practice PET chemistry is strongly in?uenced by the unique properties of the radioisotopes used (e. g. , half-life, che- cal reactivity, etc. ) and integrates scienti?c aspects of nuclear-, organic-, inorganic- and biochemistry.
List of contents
Molecular Imaging with PET - Open Questions?.- Fluorine-18 Labeling Methods: Features and Possibilities of Basic Reactions.- Fluorine-18 Labeling of Small Molecules: The Use of 18F-Labeled Aryl Fluorides Derived from No-Carrier-Added [18F]Fluoride as Labeling Precursors.- Fluorine-18 Labeling of Peptides and Proteins.- [18F]Fluoropyridines: From Conventional Radiotracers to the Labeling of Macromolecules Such as Proteins and Oligonucleotides.- Production of Non-standard PET Radionuclides and the Application of Radiopharmaceuticals Labeled with these Nuclides.- Carbon-11 Labeling Chemistry Based upon [11C]Methyl Iodide.- 68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy.- Microwaving in F-18 Chemistry: Quirks and Tweaks.- Micro-reactors for PET Tracer Labeling.- Synthesis Modules and Automation in F-18 Labeling.- Pharmacological Prerequisites for PET Ligands and Practical Issues in Preclinical PET Research.- Positron Emission Tomography Imaging as a Key Enabling Technology in Drug Development.
Summary
Personalized medicine employing patient-based tailor-made therapeutic drugs is taking over treatment paradigms in a variety of ?elds in oncology and the central nervous system. The success of such therapies is mainly dependent on ef?cacious therapeutic drugs and a selective imaging probe for identi?cation of potential responders as well as therapy monitoring for an early bene?t assessment. Molecular imaging (MI) is based on the selective and speci?c interaction of a molecular probe with a biological target which is visualized through nuclear, magnetic resonance, near infrared or other methods. Therefore it is the method of choice for patient selection and therapy monitoring as well as for speci?c e- point monitoring in modern drug development. PET (positron emitting tomography), a nuclear medical imaging modality, is ideally suited to produce three-dimensional images of various targets or processes. The rapidly increasing demand for highly selective probes for MI strongly pushes the development of new PET tracers and PET chemistry. ‘PET chemistry’ can be de?ned as the study of positron-emitting compounds regarding their synthesis, structure, composition, reactivity, nuclear properties and processes and their properties in natural and - natural environments. In practice PET chemistry is strongly in?uenced by the unique properties of the radioisotopes used (e. g. , half-life, che- cal reactivity, etc. ) and integrates scienti?c aspects of nuclear-, organic-, inorganic- and biochemistry.
